Fueling metabolic disruption via FMD to boost chemotherapy in TNBC Editorial
| Authors: | Goncalves, M. D.; Iyengar, N. M. |
| Title: | Fueling metabolic disruption via FMD to boost chemotherapy in TNBC |
| Abstract: | Triple-negative breast cancer (TNBC) is highly glycolytic and lacks effective biomarkers for therapy response. The BREAKFAST trial showed that a fasting-mimicking diet (FMD) improved pathological complete response (pCR) rates to 56.6% compared to historical chemotherapy averages (30%–40%), with minimal severe adverse events. FMD's metabolic and immune-modulating effects warrant further study with immunotherapy. © 2025 Elsevier Inc. |
| Keywords: | antineoplastic agents; note; antineoplastic agent; metabolism; pathology; patient compliance; neoadjuvant chemotherapy; drug therapy; metformin; metabolic disorder; glycolysis; fasting; pathological complete response; tumor microenvironment; adverse event; triple negative breast cancer; body weight loss; humans; human; female; triple negative breast neoplasms; fasting mimicking diet |
| Journal Title: | Cell Metabolism |
| Volume: | 37 |
| Issue: | 2 |
| ISSN: | 1550-4131 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-02-04 |
| Start Page: | 305 |
| End Page: | 306 |
| Language: | English |
| DOI: | 10.1016/j.cmet.2024.12.015 |
| PUBMED: | 39908983 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Source: Scopus |
